More recently, Ogawa et al. illustrated that transplantation of PB-CD34+ cells improved neurological functions, including grip strength test (to evaluate neuromuscular function), the water maze assay (to evaluate the spatial education skill), and the rotarod test (to evaluate sensorimotor skills) in a murine SCID chronic stroke model, providing another preclinical proof of the CD34+ therapy concept in ischemic strokes (Ogawa et al., 2022). The gene discussed is CD34; the disease is ischemic stroke.